If you have been reading about Thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-18. Numbers and descriptions here follow the published literature rather than marketing material.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
=== Naming conventions === The first part of an intein name is based on the scientific name of the organism in which it is found, and the second part is based on the name of the corresponding gene or extein. For example, the intein found in Thermoplasma acidophilum and associated with vacuolar ATPase subunit A (VMA) is called "Tac VMA". Normally, as in this example, just three letters suffice to specify the organism, but there are variations. For example, additional letters may be added to indicate a strain. If more than one intein is encoded in the corresponding gene, the inteins are given a numerical suffix starting from 5′ to 3′ or in order of their identification (for example, "Msm dnaB-1"). The segment of the gene that encodes the intein is usually given the same name as the intein, but to avoid confusion the name of the intein proper is usually capitalized (e.g., Pfu RIR1-1), whereas the name of the corresponding gene segment is italicized (e.g., Pfu rir1-1). A different disambiguating convention is to place a lowercase "i" after the source protein name, e.g. "Msm DnaBi1".
=== Analytical methods === Several relatively simple chemical tests—commercially available as reagent testing kits—can be used to assess the presence of psilocybin in extracts prepared from mushrooms. The drug produces a yellow color in the Marquis test and a green color in the Mandelin reagent. Neither of these tests is specific for psilocybin; for example, the Marquis test will react with many classes of controlled drugs, such as those containing primary amino groups and unsubstituted benzene rings, including amphetamine and methamphetamine. Ehrlich's reagent and DMACA reagent are used as chemical sprays to detect the drug after thin layer chromatography. Many modern techniques of analytical chemistry have been used to quantify psilocybin levels in mushroom samples. Although the earliest methods commonly used gas chromatography, the high temperature required to vaporize the psilocybin sample before analysis causes it to spontaneously lose its phosphoryl group and become psilocin, making it difficult to chemically discriminate between the two drugs. In forensic toxicology, techniques involving gas chromatography coupled to mass spectrometry (GC–MS) are the most widely used due to their high sensitivity and ability to separate compounds in complex biological mixtures. These techniques include ion mobility spectrometry, capillary zone electrophoresis, ultraviolet spectroscopy, and infrared spectroscopy. High-performance liquid chromatography (HPLC) is used with ultraviolet, fluorescence, electrochemical, and electrospray mass spectrometric detection methods.
== Sexual reproduction == The evolution of sexual reproduction may be a primordial and fundamental characteristic of eukaryotes, including single cell eukaryotes. Based on a phylogenetic analysis, Dacks and Roger proposed that facultative sex was present in the common ancestor of all eukaryotes. Hofstatter and Lehr reviewed evidence supporting the hypothesis that all eukaryotes can be regarded as sexual, unless proven otherwise. Sexual reproduction may have arisen in early protocells with RNA genomes (RNA world). Initially, each protocell would likely have contained one RNA genome (rather than multiple) since this maximizes the growth rate. However, the occurrence of damages to the RNA which block RNA replication or interfere with ribozyme function would make it advantageous to fuse periodically with another protocell to restore reproductive ability. This early, simple form of genetic recovery is similar to that occurring in extant segmented single-stranded RNA viruses (see influenza A virus). As duplex DNA became the predominant form of the genetic material, the mechanism of genetic recovery evolved into the more complex process of meiotic recombination, found today in most species. It thus appears likely that sexual reproduction arose early in the evolution of cells and has had a continuous evolutionary history.
6-Hydroxy-DET, or 6-HO-DET, also known as 6-hydroxy-N,N-diethyltryptamine, is a possible psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT). It is the 6-hydroxy derivative of diethyltryptamine (DET). The drug is a notable metabolite of DET.
Protein Structure drugdesign.org [1] Method_for_the_Characterization_of_the_Three-Dimensional_Structure_of_Proteins_Employing_Mass_Spectrometric_Analysis_and_Experimental-Computational_Feedback_Modeling [2] A_Method_for_the_Determination_of_the_Conformation_(Topology)_of_Proteins_Employing_Experimental-Computational_Feedback_Modeling
Sources: en.wikipedia.org
== External links == vcclab.org. Overview of the many logP and other physical property calculators available commercially and on-line. XLOGP3, a simple LogP estimator used by PubChem (release 2021.05.07)
An ion-exchange resin such as chelex 100, which contains chelating ligands bound to a polymer, can be used in water softeners and in chromatographic separation techniques. In solvent extraction the formation of electrically neutral complexes allows cations to be extracted into organic solvents. For example, in nuclear fuel reprocessing uranium(VI) and plutonium(VI) are extracted into kerosene as the complexes [MO2(TBP)2(NO3)2] (TBP = tri-n-butyl phosphate). In phase-transfer catalysis, a substance which is insoluble in an organic solvent can be made soluble by addition of a suitable ligand. For example, potassium permanganate oxidations can be achieved by adding a catalytic quantity of a crown ether and a small amount of organic solvent to the aqueous reaction mixture, so that the oxidation reaction occurs in the organic phase. In all these examples, the ligand is chosen on the basis of the stability constants of the complexes formed. For example, TBP is used in nuclear fuel reprocessing because (among other reasons) it forms a complex strong enough for solvent extraction to take place, but weak enough that the complex can be destroyed by nitric acid to recover the uranyl cation as nitrato complexes, such as [UO2(NO3)4]2− back in the aqueous phase.
=== Atomic force microscopy === Atomic force microscopy (AFM), a type of scanning force microscopy, was developed for mapping three-dimensional topographical variations in atomic surfaces with high resolution (on the order of fraction of nanometers). AFM was developed to overcome the material conduction limitations of electron transmission and scanning microscopy methods (SEM & STM). Invented by Binnig, Quate, and Gerbe in 1985, atomic force microscopy uses laser beam deflection to measure the variations in atomic surfaces. The method does not rely on the variation in electron conduction through the material, as the scanning tunneling microscope (STM) does, and therefore allow microscopy on nearly all materials, including polymers. The application of AFM on polymeric surfaces is especially favorable because polymer general lack of crystallinity leads to large variations in surface topography. Surface functionalization techniques such as grafting, corona treatment, and plasma processing increase the surface roughness greatly (compared to the unprocessed substrate surface) and are therefore accurately measured by AFM.
The precise extent to which KOR agonism underlies ibogaine's anti-addictive properties is unclear. In animal models, ibogaine administration has been shown to reduce self-administration of opioids, stimulants, and alcohol, ameliorate withdrawal symptoms, and decrease drug-seeking behavior. A 2022 systematic review of 24 studies involving 705 participants found that both ibogaine and noribogaine show promise in treating substance use disorders and comorbid depressive symptoms.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.